SLC22A4 and lung cancer: The described features suggest that OCTN1 could be exploited to target the NNCS in lung cancer, which is listed among the most aggressive human tumors, implying difficulties in pharmacological treatments due to recurrent resistance to anticancer drugs (Ashrafi et al., 2022).